DE602004025579D1 - Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus - Google Patents

Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus

Info

Publication number
DE602004025579D1
DE602004025579D1 DE602004025579T DE602004025579T DE602004025579D1 DE 602004025579 D1 DE602004025579 D1 DE 602004025579D1 DE 602004025579 T DE602004025579 T DE 602004025579T DE 602004025579 T DE602004025579 T DE 602004025579T DE 602004025579 D1 DE602004025579 D1 DE 602004025579D1
Authority
DE
Germany
Prior art keywords
polypeptides
immune response
response against
protective immune
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004025579T
Other languages
English (en)
Inventor
Annaliesa S Anderson
Kathrin Ute Jansen
Rosemarie Kelly
Loren D Schultz
Donna L Montgomery
William L Mcclements
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004025579(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE602004025579D1 publication Critical patent/DE602004025579D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602004025579T 2003-07-24 2004-07-22 Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus Active DE602004025579D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US52011503P 2003-11-14 2003-11-14
PCT/US2004/023523 WO2005009379A2 (en) 2003-07-24 2004-07-22 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (1)

Publication Number Publication Date
DE602004025579D1 true DE602004025579D1 (de) 2010-04-01

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025579T Active DE602004025579D1 (de) 2003-07-24 2004-07-22 Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus

Country Status (23)

Country Link
US (2) US20060177462A1 (de)
EP (1) EP1651166B8 (de)
JP (1) JP2007502101A (de)
KR (1) KR20060065643A (de)
AT (1) ATE457737T1 (de)
AU (1) AU2004258979B2 (de)
BR (1) BRPI0412799A (de)
CA (1) CA2532370A1 (de)
CY (1) CY1110028T1 (de)
DE (1) DE602004025579D1 (de)
DK (1) DK1651166T3 (de)
ES (1) ES2342778T3 (de)
HR (1) HRP20100240T1 (de)
IL (1) IL173253A0 (de)
IS (1) IS8213A (de)
MX (1) MXPA06000854A (de)
NO (1) NO20060898L (de)
NZ (2) NZ570750A (de)
PL (1) PL1651166T3 (de)
PT (1) PT1651166E (de)
RU (1) RU2337108C2 (de)
SI (1) SI1651166T1 (de)
WO (1) WO2005009379A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CN1918176A (zh) * 2004-02-18 2007-02-21 默克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
JP2008517900A (ja) * 2004-10-25 2008-05-29 ザ ユニバーシティ オブ ウェスタン オンタリオ スタフィロコッカス−アウレウスＩｓｄたんぱく質ベースの抗感染薬
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US20110091480A1 (en) * 2006-01-27 2011-04-21 Brown Martha J Antigen-Binding Proteins Targeting S. Aureus Orf0657n
CA2675992A1 (en) 2007-01-24 2008-11-20 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus epidermidis
EP2374466B1 (de) * 2007-05-04 2013-08-28 Krönke, Martin Impfstoff zum Schutz gegen staphylococcus aureus auf der Basis zellwandassoziierter Proteine
WO2009029132A2 (en) 2007-05-31 2009-03-05 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
EP2185195A2 (de) 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
US20110229508A1 (en) 2008-11-26 2011-09-22 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2011005341A2 (en) 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2544709A4 (de) * 2010-03-12 2014-01-08 Univ Pennsylvania Verfahren zur prävention und behandlung der kolonisierung von staphylococcus aureus sowie dadurch vermittelter infektionen und erkrankungen
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US8747858B2 (en) 2010-07-13 2014-06-10 Merck Sharp & Dohme Corp. Staphylococcus aureus surface protein SA1789 and protective vaccine based thereon
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
JP2014525429A (ja) 2011-09-01 2014-09-29 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ抗原のアジュバント添加処方物
US9527892B2 (en) 2011-10-31 2016-12-27 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2451 protein
EP2867254B1 (de) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Verfahren zum herstellen von antikörper-fc-region-konjugaten mit mindestens einer bindungsstelle, die spezifisch an ein target bindet, und verwendungen davon
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US9376487B2 (en) 2012-07-10 2016-06-28 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2493 protein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP2339344A1 (de) * 2001-06-15 2011-06-29 Inhibitex, Inc. Kreuzreaktive monoklonale und polyklonale Antikörper, die Oberflächenprotein aus koagulasenegativen Staphylococci und Staphylococcus Aureus erkennen
DE60231055D1 (de) * 2001-11-12 2009-03-19 Novo Nordisk As Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
EP1998800A2 (de) * 2006-01-18 2008-12-10 University Of Chicago Zusammensetzungen und verfahren in verbindung mit stayphylokokken-bakterienproteinen

Also Published As

Publication number Publication date
RU2337108C2 (ru) 2008-10-27
EP1651166A2 (de) 2006-05-03
EP1651166B1 (de) 2010-02-17
NZ544542A (en) 2009-01-31
US20060177462A1 (en) 2006-08-10
WO2005009379A2 (en) 2005-02-03
CA2532370A1 (en) 2005-02-03
AU2004258979A1 (en) 2005-02-03
EP1651166A4 (de) 2008-03-05
NO20060898L (no) 2006-04-24
ES2342778T3 (es) 2010-07-14
IS8213A (is) 2005-12-30
DK1651166T3 (da) 2010-05-31
SI1651166T1 (sl) 2010-06-30
KR20060065643A (ko) 2006-06-14
RU2006105498A (ru) 2006-09-10
JP2007502101A (ja) 2007-02-08
BRPI0412799A (pt) 2006-09-26
NZ570750A (en) 2009-12-24
PL1651166T3 (pl) 2010-08-31
AU2004258979B2 (en) 2007-12-06
HRP20100240T1 (hr) 2010-09-30
MXPA06000854A (es) 2006-03-30
PT1651166E (pt) 2010-04-23
CY1110028T1 (el) 2015-01-14
ATE457737T1 (de) 2010-03-15
WO2005009379A3 (en) 2006-11-30
US20100247561A1 (en) 2010-09-30
IL173253A0 (en) 2006-06-11
EP1651166B8 (de) 2010-05-19

Similar Documents

Publication Publication Date Title
ATE457737T1 (de) Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
WO2005079315A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2005086663A3 (en) Polypeptides for inducing a protective immune response against staphlococcus aureus
WO2007001361A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
IN2014CN02050A (de)
WO2006033918A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
WO2005115113A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
ATE396199T1 (de) Antimikrobielles polypeptid
WO2006078680A3 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
RS52537B (en) ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT
ATE462006T1 (de) Isoform des vegfs
NO20063026L (no) Antistoffer
WO2001064835A8 (en) Novel nucleic acids and polypeptides
ATE360701T1 (de) Putrescin-n-methyltransferasepromotor
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
DE60322613D1 (de) Frostschutzproteine aus Basidiomyceten
ATE495247T1 (de) Chromoprotein und fluoroproteine
DE50213015D1 (de) Lipase-varianten
WO2008140632A3 (en) Polypeptides for inducing a protective immune response against staphylococcus epidermidis
DK2076532T3 (da) Cytokinderivater
DE602005018369D1 (de) Neue proteine, z.b. zur verwendung für die in-vitro-isolierung und prävention von legionella pneumophila-infektionen
WO2008115415A8 (en) Polypeptides for inducing a protective immune response against staphylococcus epidermidis
DE602007006493D1 (de) Peptide mit proliferationshemmender wirkung
BR0318467A (pt) seqüências de nucleotìdeo e polipeptìdeos codificados pelas mesmas uteis para aumentar o tamanho de uma planta e aumentar o número e tamanho de folhas
SE0101519D0 (sv) Nucleic ACID

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

8363 Opposition against the patent